{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:00:36Z","timestamp":1793638836861,"version":"4.5.1"},"reference-count":199,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.kint.2024.05.015","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T07:57:35Z","timestamp":1717574255000},"page":"369-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"title":["The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-1959","authenticated-orcid":false,"given":"Marina","family":"Vivarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-7229","authenticated-orcid":false,"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Laurence H.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Fakhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-1579","authenticated-orcid":false,"given":"Daniel P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Goicoechea de Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7651-5033","authenticated-orcid":false,"given":"Marina","family":"Noris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-0192","authenticated-orcid":false,"given":"Matthew C.","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1005-3726","authenticated-orcid":false,"given":"Katalin","family":"Susztak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Thurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-2831","authenticated-orcid":false,"given":"Michael","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7369-7812","authenticated-orcid":false,"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-425X","authenticated-orcid":false,"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Alberici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Antonucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadej","family":"Avcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg M.","family":"Bajema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Chauvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Terence","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cravedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Agn\u00e8s","family":"Dragon-Durey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes B.","family":"Fogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Frazer-Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"G\u00f6rlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alister","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arenn","family":"Jauhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lafayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne D.","family":"Lanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Lemaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moglie","family":"Le Quintrec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"McAdoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R.","family":"Medjeral-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Morelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.","family":"Nester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Praga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather N.","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Rodr\u00edguez de C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Salant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Silkjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-chao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Spoleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.A.J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"van Kooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Zipfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Zuccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2024.05.015_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.ackd.2019.10.003","article-title":"Complement and the kidney: an overview","volume":"27","author":"Thurman","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib3","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3389\/fimmu.2019.02166","article-title":"Complement inhibitors in clinical trials for glomerular diseases","volume":"10","author":"Zipfel","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib4","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a Phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.05.015_bib5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib6","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","article-title":"Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial","volume":"34","author":"Garnier","year":"2023","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.05.015_bib8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.05.015_bib8a","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1681\/ASN.20233411S1988b","article-title":"An exploratory trial of an investigational RNA therapeutic, IONIS FB-LRx, for treatment of IgA nephropathy: new interim results [ASN Kidney Week 2023 abstract]","volume":"34","author":"Barbour","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib9","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.05.015_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the Factor D inhibitor danicopan: final results from two Phase 2 studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1159\/000527166","article-title":"Baseline clinical characteristics and complement biomarkers of patients with C3 glomerulopathy enrolled in two Phase 2 studies investigating the Factor D inhibitor danicopan","volume":"53","author":"Podos","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.kint.2023.11.005","article-title":"Renin and renin blockade have no role in complement activity","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.kint.2017.09.018","article-title":"C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis","volume":"93","author":"Dick","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib16","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2024.05.015_bib17","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","article-title":"Molecular mechanisms of diabetic kidney disease","volume":"124","author":"Reidy","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.05.015_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.147716","article-title":"Complement factor B in high glucose-induced podocyte injury and diabetic kidney disease","volume":"6","author":"Lu","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2024.05.015_bib19","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/jcmm.16157","article-title":"Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut-kidney axis","volume":"25","author":"Li","year":"2021","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.kint.2024.05.015_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2337\/db19-0043","article-title":"Complement C5a induces renal injury in diabetic kidney disease by disrupting mitochondrial metabolic agility","volume":"69","author":"Tan","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2024.05.015_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131849","article-title":"C3a receptor blockade protects podocytes from injury in diabetic nephropathy","volume":"5","author":"Morigi","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2024.05.015_bib22","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.2337\/diabetes.53.6.1570","article-title":"Association between mannose-binding lectin and vascular complications in type 1 diabetes","volume":"53","author":"Hansen","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2024.05.015_bib23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00125-004-1594-1","article-title":"Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy","volume":"48","author":"Saraheimo","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2024.05.015_bib24","doi-asserted-by":"crossref","first-page":"29013","DOI":"10.1073\/pnas.2005905117","article-title":"Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease","volume":"117","author":"Sheng","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2024.05.015_bib25","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1073\/pnas.97.10.5450","article-title":"Molecular basis for a link between complement and the vascular complications of diabetes","volume":"97","author":"Acosta","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2024.05.015_bib26","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.2337\/db10-1181","article-title":"Transcriptome analysis of human diabetic kidney disease","volume":"60","author":"Woroniecka","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2024.05.015_bib27","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191699","article-title":"Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis","volume":"217","author":"Angeletti","year":"2020","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.kint.2024.05.015_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130986","article-title":"C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis","volume":"4","author":"Han","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2024.05.015_bib29","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.kint.2019.04.028","article-title":"Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis","volume":"96","author":"van de Lest","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136558","article-title":"Complement activation in patients with focal segmental glomerulosclerosis","volume":"10","author":"Thurman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2024.05.015_bib31","doi-asserted-by":"crossref","first-page":"F505","DOI":"10.1152\/ajprenal.00041.2021","article-title":"Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome","volume":"321","author":"Trachtman","year":"2021","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2024.05.015_bib32","article-title":"Complement deposition predicts worsening kidney function and underlines the clinical significance of the 2010 Renal Pathology Society Classification of Diabetic Nephropathy","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.molimm.2019.07.031","article-title":"Role of complement in diabetes","volume":"114","author":"Ajjan","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib34","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/ki.1987.72","article-title":"Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis","volume":"31","author":"Rauterberg","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0272-6386(00)70296-4","article-title":"Activation of the acute phase response and complement C3 in patients with IgA nephropathy","volume":"35","author":"Janssen","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000013568","article-title":"Significance of glomerular deposition of C3c and C3d in IgA nephropathy","volume":"20","author":"Nakagawa","year":"2000","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/adc.53.5.417","article-title":"Serum complement components in Henoch-Schonlein purpura","volume":"53","author":"Garcia-Fuentes","year":"1978","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.kint.2024.05.015_bib38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00467-019-04445-x","article-title":"Clinical relevance of membrane attack complex deposition in children with IgA nephropathy and Henoch-Schonlein purpura","volume":"35","author":"Dumont","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(83)92065-2","article-title":"Vascular IgA and C3 deposition in gastrointestinal tract of patients with Henoch-Schoenlein purpura","volume":"1","author":"Touchard","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.05.015_bib40","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/0016-5085(82)90080-4","article-title":"Jejunal IgA and C3 deposition in adult Henoch-Schonlein purpura with severe intestinal manifestations","volume":"82","author":"Morichau-Beauchant","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2024.05.015_bib41","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.4049\/jimmunol.167.5.2861","article-title":"Human IgA activates the complement system via the mannan-binding lectin pathway","volume":"167","author":"Roos","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib42","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib43","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2215\/CJN.02530317","article-title":"Mesangial C4d deposits in early IgA nephropathy","volume":"13","author":"Segarra","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib44","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1681\/ASN.2017010076","article-title":"Mannose-binding lectin levels could predict prognosis in IgA nephropathy","volume":"28","author":"Guo","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1053\/j.ajkd.2004.10.020","article-title":"Activation of the lectin complement pathway in Henoch-Schonlein purpura nephritis","volume":"45","author":"Hisano","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.molimm.2022.01.011","article-title":"Lectin and alternative complement pathway activation in cutaneous manifestations of IgA-vasculitis: a new target for therapy?","volume":"143","author":"Damman","year":"2022","journal-title":"Mol Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib47","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1681\/ASN.2014010096","article-title":"Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy","volume":"26","author":"Zhu","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.kint.2018.02.023","article-title":"Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy","volume":"94","author":"Zhu","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib49","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","article-title":"Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy","volume":"92","author":"Medjeral-Thomas","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib50","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ekir.2017.11.015","article-title":"Progressive IgA nephropathy is associated with low circulating mannan-binding lectin-associated serine protease-3 (MASP-3) and increased glomerular factor H-related protein-5 (FHR5) deposition","volume":"3","author":"Medjeral-Thomas","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.05.015_bib51","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1038\/s41598-021-84715-7","article-title":"A\u00a0multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy","volume":"11","author":"Tan","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2024.05.015_bib52","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5414\/CN107854","article-title":"Association of C1q deposition with renal outcomes in IgA nephropathy","volume":"80","author":"Lee","year":"2013","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib53","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.kint.2022.02.042","article-title":"Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy","volume":"102","author":"Barbour","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib54","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.kint.2020.04.042","article-title":"Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool","volume":"98","author":"Barbour","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.572754","article-title":"Monitoring immune responses in IgA nephropathy: biomarkers to guide management","volume":"11","author":"Selvaskandan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib56","first-page":"2141","article-title":"IgA vasculitis complicated by acute kidney failure with thrombotic microangiopathy: successful use of eculizumab","volume":"34","author":"Patel","year":"2021","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib57","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1159\/000508841","article-title":"Inhibition of the lectin pathway of the complement system as a novel approach in the management of IgA vasculitis-associated nephritis","volume":"144","author":"Selvaskandan","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2024.05.015_bib58","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.transproceed.2017.02.044","article-title":"First treatment of relapsing rapidly progressive IgA nephropathy with eculizumab after living kidney donation: a case report","volume":"49","author":"Herzog","year":"2017","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2024.05.015_bib59","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000485194","article-title":"Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy: a case report successfully treated with eculizumab","volume":"138","author":"Nakamura","year":"2018","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2024.05.015_bib60","first-page":"24","article-title":"Coexistence of atypical hemolytic uremic syndrome and crescentic IgA nephropathy treated with eculizumab: a case report","volume":"4","author":"Matsumura","year":"2016","journal-title":"Clin Nephrol Case Stud"},{"key":"10.1016\/j.kint.2024.05.015_bib61","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00467-014-2863-y","article-title":"Eculizumab treatment for rescue of renal function in IgA nephropathy","volume":"29","author":"Rosenblad","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib62","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ckj\/sfv076","article-title":"Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum?","volume":"8","author":"Ring","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.05.015_bib63","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.05.015_bib64","article-title":"POS-546 Efficacy and safety of iptacopan in IgA nephropathy: results of a randomized double-blind placebo-controlled phase 2 study at 6 months","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.05.015_bib65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.kint.2023.10.035","article-title":"Complement activation and effector pathways in membranous nephropathy","volume":"105","author":"Kistler","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib66","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI109987","article-title":"A\u00a0new role for complement in experimental membranous nephropathy in rats","volume":"66","author":"Salant","year":"1980","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.05.015_bib67","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1172\/JCI111159","article-title":"Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit","volume":"72","author":"Groggel","year":"1983","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.05.015_bib68","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4049\/jimmunol.137.5.1511","article-title":"The membrane attack complex in complement-mediated glomerular epithelial cell injury: formation and stability of C5b-9 and C5b-7 in rat membranous nephropathy","volume":"137","author":"Cybulsky","year":"1986","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib69","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1046\/j.1523-1755.2003.00305.x","article-title":"Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy","volume":"64","author":"Saran","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib70","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/modpathol.2012.237","article-title":"IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression","volume":"26","author":"Huang","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2024.05.015_bib71","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1681\/ASN.2015101155","article-title":"Phospholipase A2 receptor-related membranous nephropathy and mannan-binding lectin deficiency","volume":"27","author":"Bally","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib72","first-page":"295","article-title":"C4d as a diagnostic tool in membranous nephropathy","volume":"32","author":"Espinosa-Hernandez","year":"2012","journal-title":"Nefrologia"},{"key":"10.1016\/j.kint.2024.05.015_bib73","first-page":"1391","article-title":"C4d immunohistochemical staining is a sensitive method to confirm immunoreactant deposition in formalin-fixed paraffin-embedded tissue in membranous glomerulonephritis","volume":"26","author":"Val-Bernal","year":"2011","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.kint.2024.05.015_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.05.015_bib75","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1681\/ASN.2021101384","article-title":"Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy","volume":"33","author":"Gao","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib76","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/ndt\/gfx235","article-title":"Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy","volume":"33","author":"Hayashi","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.05.015_bib77","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib78","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1053\/j.ajkd.2020.04.013","article-title":"Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study","volume":"76","author":"Hanset","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib79","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/ckj\/sfab069","article-title":"Membranous nephropathy: a single disease or a pattern of injury resulting from different diseases","volume":"14","author":"Sethi","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.05.015_bib80","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2024.05.015_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.909503","article-title":"Post-transplant thrombotic microangiopathy due to a pathogenic mutation in complement Factor I in a patient with membranous nephropathy: case report and review of literature","volume":"13","author":"Saleem","year":"2022","journal-title":"Front. Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib82","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/0961203310371154","article-title":"The complex nature of serum C3 and C4 as biomarkers of lupus renal flare","volume":"19","author":"Birmingham","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2024.05.015_bib83","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/09612033221074580","article-title":"The association between lupus serology and disease outcomes: a systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus","volume":"31","author":"Kostopoulou","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.kint.2024.05.015_bib84","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib85","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aao4555","article-title":"C1q restrains autoimmunity and viral infection by regulating CD8(+) T cell metabolism","volume":"360","author":"Ling","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.kint.2024.05.015_bib86","article-title":"Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care","volume":"32","author":"Castrej\u00f3n","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.kint.2024.05.015_bib87","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11926-021-00984-1","article-title":"A\u00a0review of complement activation in SLE","volume":"23","author":"Weinstein","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.kint.2024.05.015_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000459","article-title":"Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme","volume":"8","author":"Maslen","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.kint.2024.05.015_bib89","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib90","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/acr.20397","article-title":"Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide","volume":"63","author":"Dall'Era","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.kint.2024.05.015_bib91","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00005792-199501000-00003","article-title":"Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients","volume":"74","author":"Wisnieski","year":"1995","journal-title":"Medicine"},{"key":"10.1016\/j.kint.2024.05.015_bib92","first-page":"2286","article-title":"Eculizumab as rescue therapy in severe resistant lupus nephritis","volume":"54","author":"Pickering","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.kint.2024.05.015_bib93","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy","volume":"30","author":"Coppo","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib94","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.4049\/jimmunol.1402956","article-title":"Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis","volume":"194","author":"Giles","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib95","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.ekir.2021.05.029","article-title":"The influence of an elastase-sensitive complement C5 variant on lupus nephritis and its flare","volume":"6","author":"Toy","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.05.015_bib96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/rheumatology\/39.2.133","article-title":"Links between complement abnormalities and systemic lupus erythematosus","volume":"39","author":"Pickering","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.kint.2024.05.015_bib97","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/art.20561","article-title":"Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus","volume":"50","author":"Manzi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2024.05.015_bib98","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3389\/fimmu.2018.01388","article-title":"Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications","volume":"9","author":"Tedesco","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib99","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the pathophysiology of the antiphospholipid syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.kint.2024.05.015_bib101","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.autrev.2019.03.015","article-title":"Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab","volume":"18","author":"Ruffatti","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2024.05.015_bib102","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1160\/TH11-08-0554","article-title":"Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome","volume":"107","author":"Breen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.kint.2024.05.015_bib103","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","article-title":"Complement activation in patients with primary antiphospholipid syndrome","volume":"68","author":"Oku","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib104","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3389\/fimmu.2019.00773","article-title":"Blood cell-bound C4d as a marker of complement activation in patients with the antiphospholipid syndrome","volume":"10","author":"Lonati","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib105","first-page":"2088","article-title":"High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets","volume":"40","author":"Ruffatti","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.kint.2024.05.015_bib106","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/biomedicines9060671","article-title":"Low preconception complement levels are associated with adverse pregnancy outcomes in a multicenter study of 260 pregnancies in 197 women with antiphospholipid syndrome or carriers of antiphospholipid antibodies","volume":"9","author":"Nalli","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.kint.2024.05.015_bib107","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2017-212224","article-title":"Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and\/or antiphospholipid antibodies","volume":"77","author":"Kim","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201cCAPS Registry.\u201d","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2024.05.015_bib109","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib110","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.kint.2024.05.015_bib111","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib112","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s10875-008-9268-2","article-title":"Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis","volume":"29","author":"Xing","year":"2009","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib113","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2012.313","article-title":"Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"83","author":"Gou","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib114","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2024.05.015_bib115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib116","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.kint.2024.05.015_bib117","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib117a","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal thrombotic microangiopathy: a review","volume":"81","author":"Genest","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib118","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy","volume":"97","author":"Brocklebank","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib119","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.1200679","article-title":"Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome","volume":"189","author":"Blanc","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib120","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.kint.2024.05.015_bib121","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex\u00a0vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib122","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.kint.2024.05.015_bib123","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.kint.2024.05.015_bib124","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2024.05.015_bib125","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2020006931","article-title":"Familial risk of developing atypical hemolytic-uremic syndrome","volume":"136","author":"Arjona","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.kint.2024.05.015_bib126","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib127","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ckj\/sfab005","article-title":"Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes","volume":"14","author":"Ariceta","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.05.015_bib128","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1469-1809.2011.00671.x","article-title":"Age-related penetrance of hereditary atypical hemolytic uremic syndrome","volume":"75","author":"Sullivan","year":"2011","journal-title":"Ann Hum Genet"},{"key":"10.1016\/j.kint.2024.05.015_bib129","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib130","doi-asserted-by":"crossref","DOI":"10.1053\/ajkd.2002.36938","article-title":"Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor","volume":"40","author":"Donne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib131","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.05.015_bib132","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.05.015_bib133","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","article-title":"Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series","volume":"70","author":"Duineveld","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib134","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib135","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib136","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.kint.2024.05.015_bib137","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/bloodadvances.2020003175","article-title":"Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome","volume":"5","author":"Chaturvedi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.kint.2024.05.015_bib138","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.4049\/jimmunol.137.11.3414","article-title":"Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells","volume":"137","author":"Gutstein","year":"1986","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib139","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.05.015_bib140","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-0040-1713111","article-title":"Acute myocarditis and eculizumab caused severe cholestasis in a 17-month-old child who has hemolytic uremic syndrome associated with shiga toxin-producing Escherichia coli","volume":"10","author":"Yesilbas","year":"2021","journal-title":"J\u00a0Pediatr Intensive Care"},{"key":"10.1016\/j.kint.2024.05.015_bib141","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00467-019-04234-6","article-title":"Escherichia coli-associated hemolytic uremic syndrome and severe chronic hepatocellular cholestasis: complication or side effect of eculizumab?","volume":"34","author":"Mauras","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib142","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib143","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"4S","key":"10.1016\/j.kint.2024.05.015_bib144","first-page":"S1","article-title":"KDIGO 2021 Clinical Practice Guideline for the\u00a0Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib145","first-page":"165","article-title":"Membranoproliferative glomerulonephritis associated with autoimmune diseases","volume":"27","author":"Zand","year":"2014","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib146","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ki.2012.407","article-title":"Bacterial infection-related glomerulonephritis in adults","volume":"83","author":"Nasr","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib147","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2009010110","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits","volume":"20","author":"Nasr","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib148","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2215\/CJN.0000000000000252","article-title":"Rare variants in complement gene in C3 glomerulopathy and immunoglobulin-mediated membranoproliferative GN","volume":"18","author":"Meuleman","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib149","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib150","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1681\/ASN.2015040385","article-title":"High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies","volume":"27","author":"Bu","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib151","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0140-6736(10)60670-8","article-title":"Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis","volume":"376","author":"Gale","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.05.015_bib152","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1681\/ASN.2012020166","article-title":"A\u00a0hybrid CFHR3-1 gene causes familial C3 glomerulopathy","volume":"23","author":"Malik","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib153","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1172\/JCI68280","article-title":"C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation","volume":"123","author":"Tortajada","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.05.015_bib154","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1172\/JCI71866","article-title":"Complement factor H-related hybrid protein deregulates complement in dense deposit disease","volume":"124","author":"Chen","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.05.015_bib155","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.kint.2017.04.025","article-title":"A\u00a0novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy","volume":"92","author":"Togarsimalemath","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib156","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1172\/JCI43343","article-title":"Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation","volume":"120","author":"Mart\u00ednez-Barricarte","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.05.015_bib157","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1681\/ASN.2015040348","article-title":"A\u00a0familial C3GN secondary to defective C3 regulation by complement receptor 1 and complement Factor H","volume":"27","author":"Chauvet","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib158","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ki.1986.278","article-title":"H\u00a0deficiency in two brothers with atypical dense intramembranous deposit disease","volume":"30","author":"Levy","year":"1986","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib159","doi-asserted-by":"crossref","first-page":"25168","DOI":"10.1074\/jbc.272.40.25168","article-title":"Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism","volume":"272","author":"Ault","year":"1997","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2024.05.015_bib160","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.kint.2020.05.028","article-title":"Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome","volume":"98","author":"Zhang","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib161","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1681\/ASN.2019040433","article-title":"Large-scale whole-genome sequencing reveals the genetic architecture of primary membranoproliferative GN and C3 glomerulopathy","volume":"31","author":"Levine","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib162","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2249.1993.tb05917.x","article-title":"Molecular analysis of C3 allotypes in patients with nephritic factor","volume":"91","author":"Finn","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib163","doi-asserted-by":"crossref","first-page":"9475","DOI":"10.1074\/jbc.M709587200","article-title":"Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations","volume":"283","author":"Hocking","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2024.05.015_bib164","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.1073\/pnas.1019338108","article-title":"Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk","volume":"108","author":"Heurich","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2024.05.015_bib165","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1038\/s41598-017-05173-8","article-title":"A\u00a0haplotype in CFH family genes confers high risk of rare glomerular nephropathies","volume":"7","author":"Ding","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2024.05.015_bib166","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib166a","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ekir.2023.11.025","article-title":"Defining nephritic factors as diverse drivers of systemic complement dysregulation in C3 glomerulopathy","volume":"9","author":"Hauer","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.05.015_bib167","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.3389\/fimmu.2018.02329","article-title":"Unraveling the molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and IC-MPGN","volume":"9","author":"Donadelli","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2024.05.015_bib168","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.kint.2022.05.027","article-title":"Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy","volume":"102","author":"Chauvet","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib169","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/ckj\/sfz073","article-title":"Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis","volume":"13","author":"Garam","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.05.015_bib170","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex-mediated membranoproliferative GN","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib171","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1681\/ASN.2019080851","article-title":"Anti-factor B antibodies and acute postinfectious GN in children","volume":"31","author":"Chauvet","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib171a","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy\u2013associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.kint.2024.05.015_bib172","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/ndt\/gfab302","article-title":"C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies","volume":"37","author":"Caravaca-Font\u00e1n","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.05.015_bib173","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy\u2014understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib174","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib175","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.kint.2018.04.004","article-title":"Aliskiren inhibits renin-mediated complement activation","volume":"94","author":"B\u00e9k\u00e1ssy","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib176","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib177","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2020.11.011","article-title":"Validation of a histologic scoring index for C3 glomerulopathy","volume":"77","author":"Caravaca-Font\u00e1n","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib178","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib179","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib180","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib181","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/ckj\/sfy127","article-title":"Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy","volume":"12","author":"Bharati","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.05.015_bib182","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: is it really effective?","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib183","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00467-020-04736-8","article-title":"Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis","volume":"36","author":"Khandelwal","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib184","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years' experience at Mayo Clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.kint.2024.05.015_bib185","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib186","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib187","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/j.ajkd.2018.12.046","article-title":"C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial","volume":"74","author":"Ruggenenti","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.015_bib188","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.ki.5000269","article-title":"Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)","volume":"70","author":"Licht","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.015_bib189","unstructured":"Bomback, A. Orally administered C5AR inhibitor avacopan in a randomized, double-blind, placebo-controlled study (ACCOLADE) for treatment of C3 glomerulopathy. European Renal Association-European Dialysis and Transplant Association 2021 Congress. Virtual. Oral Presentation LB001. Accessed July\u00a08, 2024. https:\/\/era-apps.m-anage.com\/eraedta21\/en-GB\/pag\/presentation\/493961"},{"key":"10.1016\/j.kint.2024.05.015_bib190","volume":"32","author":"Wong","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib191","article-title":"C3 inhibition with pegcetacoplan targets the underlying disease process of C3 glomerulopathy (C3G) and improves proteinuria","author":"Dixon","year":"2020","journal-title":"ASN Kidney Week"},{"key":"10.1016\/j.kint.2024.05.015_bib192","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00467-018-3989-0","article-title":"Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"34","author":"Noris","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2024.05.015_bib193","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ndt\/gfab075","article-title":"Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.05.015_bib194","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2024.05.015_bib195","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824003892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824003892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:12:12Z","timestamp":1732162332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253824003892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":199,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0085253824003892"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2024.05.015","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.05.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}